Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent

A controlled-release pharmaceutical dosage form comprising:

• a CpG oligodeoxynucleotide nano-cocoon, wherein the nano-cocoon comprises an immunotherapeutic agent and inflammation-responsive nanoparticles, wherein the nanoparticles encapsulate a restriction enzyme, wherein the inflammation-responsive nanoparticles comprise triglycerol monostearate (TGMS), and wherein the restriction enzyme is HhaI, and wherein the immunotherapeutic agent is selected from an anti-PD1 antibody, an anti-PDL1 antibody, an anti-CTLA4 antibody, or a combination thereof.